Vertex Pharma, US92532F1003

Vertex Pharmaceuticals stock slips 1.33% below Xetra close

Published on 11/20/2026 at 17:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Vertex Pharmaceuticals stock is heading toward a November 30 FDA decision on povetacicept. Vertex is broadening its commercial portfolio beyond cystic fibrosis.

Key points for Vertex investors

  • The company is approaching a November 30 FDA decision on povetacicept for IgA nephropathy.
  • Vertex raised its full-year 2026 revenue guidance after third-quarter revenue growth.
  • The pipeline and recent Crinetics acquisition are expanding Vertex beyond its cystic fibrosis franchise.
Vertex Pharma, US92532F1003, Illustration mit AI erstellt.

On Friday, November 20, Vertex Pharmaceuticals stock traded at 477.35 euros on Lang & Schwarz at 17:05 CET, 1.33% below the Xetra close of Wednesday, November 18, according to Yahoo Finance historical prices. Compared with the 490.55-euro level published on November 19, the quote was 2.69% lower.

Regulatory catalyst remains ahead

Vertex is approaching a key regulatory date for povetacicept, its investigational treatment for IgA nephropathy. The U.S. Food and Drug Administration has set November 30 as the target action date for the application, according to the company's November 2 results release.

The regulatory decision could determine the timing of Vertex's entry into nephrology. The company said the application is supported by interim Phase 3 RAINIER data and that an approval would establish a fifth commercial franchise.

Growth beyond cystic fibrosis

Vertex reported third-quarter revenue of 3.44 billion US dollars, up 12% from the year-earlier period, and raised its full-year 2026 revenue guidance to 13.15 billion to 13.25 billion US dollars. The release also highlighted contributions from CASGEVY, JOURNAVX and PALSONIFY alongside continued strength in cystic fibrosis medicines.

The Crinetics Pharmaceuticals acquisition added PALSONIFY to the commercial portfolio and expanded Vertex's rare-endocrine presence. Management is also advancing programs in pain, kidney disease, diabetes and other areas, increasing the number of potential future growth drivers while adding development and integration demands.

US market participants can follow Current market reports.

More news and analyses on Vertex Pharmaceuticals stock.

Vertex Pharmaceuticals

  • ISIN: US92532F1003
  • Ticker: VRTX
  • Home exchange: Nasdaq
  • Trading venue: Lang & Schwarz
  • Price: 477.35 euros on November 20, 2026, at 17:05 CET
  • Daily comparison: 1.33% below the Xetra close of November 18, 2026
  • Xetra close: 483.80 euros on November 18, 2026
Disclaimer...
en | US92532F1003 | VERTEX PHARMA | boerse | 70540571 | bgmi